TSS
XLO icon

Two Sigma Securities’s Xilio Therapeutics XLO Stock Holding History

Two Sigma Securities’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,295
Closed -$27.1K – 2094
2025
Q3 		$27.1K Buy
+2,295
New +$23K ﹤0.01% 1081
2024
Q4 		– Sell
-3,175
Closed -$35K – 3373
2024
Q3 		$35K Buy
3,175
+2,227
+235% +$27.3K ﹤0.01% 2414
2024
Q2 		$12.6K Buy
+948
New +$14.8K ﹤0.01% 2780

Other funds holding XLO

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Two Sigma Securities's XLO Position: Q4 2025 in Review

Two Sigma Securities sold out of Xilio Therapeutics (XLO) in Q4 2025, closing a stake of 2,295 shares — an estimated $27.1K sold.

Two Sigma Securities first reported a position in XLO in Q2 2024 and held it in 3 quarters. The position peaked at $35K in Q3 2024. 37 funds tracked by Wall St. Rank hold XLO as of Q4 2025.

  • Two Sigma Securities reported no remaining Xilio Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Securities sold 2,295 Xilio Therapeutics shares in Q4 2025, an estimated $27.1K.
  • Two Sigma Securities first reported a position in Xilio Therapeutics in Q2 2024 and held it in 3 quarters.
  • Two Sigma Securities's Xilio Therapeutics position peaked at $35K in Q3 2024.
  • 37 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.